Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions by Payne, RO et al.
This is a repository copy of Human vaccination against RH5 induces neutralizing 
antimalarial antibodies that inhibit RH5 invasion complex interactions.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/147846/
Version: Published Version
Article:
Payne, RO orcid.org/0000-0002-8490-671X, Silk, SE, Elias, SC et al. (39 more authors) 
(2017) Human vaccination against RH5 induces neutralizing antimalarial antibodies that 
inhibit RH5 invasion complex interactions. JCI insight, 2 (21). e96381. ISSN 2379-3708 
https://doi.org/10.1172/jci.insight.96381
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of th
	
		
	

		
		
		

			

			

	
	
		
	
 !"#$%&'($))*+) ),-+%&'(
 
.*/0	+
00-//	--		1
	+-+		*-
	*/		*-	0			2-
	
--
34*++5"65#	+*	+4*3
	+-	**		+*	-		40-0+-	+	
+-	+
1
70--		1*+
	65	+8	*3-			2	*
9	
			3	/
	*/7:*	4*/	/--	3*0--	:
	*/
&'";*&'#	*		*</*0*/	--	/
1		"=#-*+650' -0=	--
	**	+34++	(31/		*
	*=	--3*-*	365	4*<4*-3	0-	
+4	-/
">2#/	+*		*-0		
65	*4*1
	-65/	-<.0
1*+	4		653-0-	/4*-*4

:		/+	
<-*+	4*

4/*0-		*0+
	0					<.*		
+06534	*/	--	00-	-
+

	 
		 	
	


	
$)),-)%&'(3*0
1insight.jci.org   https://doi.org/10.1172/jci.insight.96381
R E S E A R C H  A R T I C L E
Conflict of interest: S.J. Draper is a 
named inventor on patent applications 
relating to RH5 and/or other malaria 
vaccines and immunization regimens; 
is a cofounder of, shareholder in, and 
consultant for SpyBiotech; and declares 
research funding support from Pfizer 
and GSK BioPharm. A.D. Douglas, 
G.J. Wright, and A.V.S. Hill are named 
inventors on patent applications relating 
to RH5 and/or other malaria vaccines 
and immunization regimens. L. Siani and 
S. Di Marco are employees of ReiThera 
(formerly Okairos), which is currently 
developing vectored vaccines for a 
number of diseases. J. Vekemans was an 
employee of GSK, which has acquired the 
ChAd63 vector from Okairos. R. Ashfield 
is a director of Ducentis and holds shares 
in the company, which is developing a 
therapy for autoimmune disease. A.M. 
Minassian has an immediate family 
member who is an inventor on patents 
relating to RH5 and/or other malaria 
vaccines and immunization regimens 
and who is a cofounder of, shareholder 
in, and consultant for SpyBiotech. S. 
Biswas is a cofounder and CEO of, and 
shareholder in, SpyBiotech and is a 
contributor in a patent application 
relating to multimerisation technology. 
J. Jin is a cofounder of and shareholder 
in SpyBiotech.
License: This work is licensed under 
the Creative Commons Attribution 
4.0 International License. To view 
a copy of this license, visit http://
creativecommons.org/licenses/by/4.0/.
Submitted: July 31, 2017 
Accepted: October 5, 2017 
Published: xxxx
Reference information: 
JCI Insight. 2017;2(21):e96381. 
https://doi.org/10.1172/jci.
insight.96381.
Human vaccination against RH5 induces 
neutralizing antimalarial antibodies that 
inhibit RH5 invasion complex interactions
Ruth O. Payne,1 Sarah E. Silk,1 Sean C. Elias,1 Kazutoyo Miura,2 Ababacar Diouf,2 Francis Galaway,3 
Hans de Graaf,4 Nathan J. Brendish,4 Ian D. Poulton,1 Oliver J. Gri ths,1 Nick J. Edwards,1 Jing Jin,1 
Geneviève M. Labbé,1 Daniel G.W. Alanine,1 Loredana Siani,5 Stefania Di Marco,5 Rachel Roberts,1 
Nicky Green,6 Eleanor Berrie,6 Andrew S. Ishizuka,1 Carolyn M. Nielsen,1 Martino Bardelli,1  
Frederica D. Partey,1,7,8 Michael F. Ofori,8 Lea Barfod,1 Juliana Wambua,9 Linda M. Murungi,1,9  
Faith H. Osier,9 Sumi Biswas,1 James S. McCarthy,10 Angela M. Minassian,1 Rebecca Ashield,1  
Nicola K. Viebig,11 Fay L. Nugent,1 Alexander D. Douglas,1 Johan Vekemans,12 Gavin J. Wright,3  
Saul N. Faust,4 Adrian V.S. Hill,1 Carole A. Long,2 Alison M. Lawrie,1 and Simon J. Draper1
1The Jenner Institute, University of Oxford, Oxford, United Kingdom. 2Laboratory of Malaria and Vector Research, 
NIAID/NIH, Rockville, Maryland, USA. 3Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Cambridge, 
United Kingdom. 4NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation 
Trust and Faculty of Medicine, University of Southampton, Southampton, United Kingdom. 5ReiThera SRL (formerly 
Okairos SRL), Viale Città d’Europa, Rome, Italy. 6Clinical Biomanufacturing Facility, University of Oxford, Oxford, United 
Kingdom. 7Centre for Medical Parasitology, Department of Immunology and Microbiology (ISIM), Faculty of Health and 
Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 8Department of Immunology, Noguchi Memorial 
Institute for Medical Research, University of Ghana, Legon, Ghana. 9KEMRI Centre for Geographic Medicine Research, 
Kilifi, Kenya. 10QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. 11European Vaccine Initiative, 
UniversitätsKlinikum Heidelberg, Heidelberg, Germany. 12GSK Vaccines, Wavre, Belgium.
Introduction
The most severe form of  human malaria is caused by the Plasmodium falciparum parasite. Despite recent and 
encouraging advances in malaria control measures, current estimates suggest that, in 2015, there were still 
over 200 million clinical cases leading to 438,000 deaths (1). Consequently, the development of  an effective 
and durable vaccine remains a key strategic goal to aid the control, local elimination, and eventual eradica-
tion of  this disease (2). The mainstay approach to vaccination against the blood-stage of  malaria infection 
is to induce antibodies against the merozoite form of  the parasite that invades erythrocytes (3). Such a vac-
The development of a highly efective vaccine remains a key strategic goal to aid the control and 
eventual eradication of Plasmodium falciparum malaria. In recent years, the reticulocyte-binding 
protein homolog 5 (RH5) has emerged as the most promising blood-stage P. falciparum candidate 
antigen to date, capable of conferring protection against stringent challenge in Aotus monkeys. 
We report on the irst clinical trial to our knowledge to assess the RH5 antigen — a dose-escalation 
phase Ia study in 24 healthy, malaria-naive adult volunteers. We utilized established viral vectors, 
the replication-deicient chimpanzee adenovirus serotype 63 (ChAd63), and the attenuated 
orthopoxvirus modiied vaccinia virus Ankara (MVA), encoding RH5 from the 3D7 clone of P. 
falciparum. Vaccines were administered i.m. in a heterologous prime-boost regimen using an 
8-week interval and were well tolerated. Vaccine-induced anti-RH5 serum antibodies exhibited 
cross-strain functional growth inhibition activity (GIA) in vitro, targeted linear and conformational 
epitopes within RH5, and inhibited key interactions within the RH5 invasion complex. This is 
the irst time to our knowledge that substantial RH5-speciic responses have been induced by 
immunization in humans, with levels greatly exceeding the serum antibody responses observed in 
African adults following years of natural malaria exposure. These data support the progression of 
RH5-based vaccines to human eicacy testing.
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cine would protect against disease severity and could reduce transmission by accelerating the control and 
clearance of  blood-stage parasitemia, either in a standalone manner or by complementing preerythrocytic 
immunity induced by partially effective subunit (4) or whole sporozoite vaccine strategies (5).
However, despite the fact that naturally acquired immunity to malaria is largely directed against the 
blood-stage parasite (6), the development of  an effective vaccine has proved exceptionally challenging. 
The most widely studied merozoite candidate vaccine antigens have been hindered by substantial levels of  
polymorphism (7) alongside redundant erythrocyte invasion pathways (8). Extremely high concentrations 
of  functional antibody against these antigens have also been required to neutralize the parasite (9), likely 
linked to the kinetic constraints imposed by very rapid erythrocyte invasion (10). Nevertheless, substantial 
progress has been made in recent years, with the identification of  a new generation of  merozoite antigen 
targets that are essential and that exhibit relatively low levels of  polymorphism, leading to induction of  
strain-transcending antibodies by vaccination in preclinical models (11). Three of  these targets form a com-
plex, including the P. falciparum reticulocyte–binding protein homolog 5 (RH5) (12), the cysteine-rich pro-
tective antigen (CyRPA) (13), and the RH5-interacting protein (Ripr) (14). Of  these, vaccine development 
efforts are currently most advanced for RH5 (15).
The first vaccination studies with RH5 used regions of  the antigen made in E. coli that failed to induce 
functional antibodies (16, 17). However, functional neutralizing antibodies were subsequently generated by 
using immunogens based on the full-length RH5 (RH5_FL) sequence. These antibodies raised by vaccina-
tion of  animals can cross-inhibit all P. falciparum lines and field isolates tested to date (12, 18–20), notably 
with higher efficiency than other historical target antigens (18). RH5 is also essential (16, 21) and forms a 
critical nonredundant interaction with its receptor basigin (CD147) on the RBC surface (22). Somewhat 
surprisingly, RH5 appears to be under relatively low-level immune pressure following natural infection 
(12, 23–26), with functional constraints also linked to basigin binding and host RBC tropism (21, 27, 28) 
— both of  these factors potentially explain its relatively high degree of  sequence conservation. Recently, 
the N-terminal region of  RH5 (RH5Nt) has been shown to bind the essential glycosylphosphatidylinosi-
tol-anchored (GPI-anchored) merozoite protein P113, providing a mechanism for anchoring RH5 to the 
merozoite surface (29). When bound by P113, RH5_FL is able to bind basigin and CyRPA, but not Ripr. 
CyRPA, however, can bind Ripr and likely recruits this molecule to the complex leading to its one-way 
release from P113, either by proteolytic cleavage of  RH5Nt or mutually exclusive binding of  P113 and Ripr. 
The function of  the RH5-CyRPA-Ripr complex has been linked to pore formation between the merozoite 
and the RBC, allowing for the movement of  Ca2+ into the host cell and alterations in RBC cytoskeleton 
architecture, prior to establishment of  the tight junction (30, 31).
The traditional approach to antibody induction by vaccination has been the delivery of  recombinant 
protein, or particle-in-adjuvant formulations. An alternative strategy, developed over the last decade, has seen 
the use of  recombinant viral vectored vaccines to deliver protein antigens of  interest, whereby the design 
and administration of  these vectors has been optimized to induce antibodies in conjunction with the T cell 
responses for which they were historically favored (32, 33). Such a strategy is particularly attractive when 
the antigen of  interest is refractory to production in recombinant form using heterologous expression plat-
forms. Indeed, the RH5_FL protein proved particularly difficult to express for many years, with the first 
highly promising vaccine data generated by use of  the viral vector platform (12). In the case of  this approach, 
a recombinant replication–deficient adenovirus (of  human or simian serotype) is used to prime the immune 
response, followed by a booster vaccination (typically 8 weeks later) with an attenuated poxvirus recombinant 
for the same antigen (33). This heterologous prime-boost approach has shown antibody induction against 
difficult-to-express malaria antigens in numerous animal models, including nonhuman primates (32, 34, 35). 
These vectors, delivering antigens from P. falciparum, have now been shown to be safe and immunogenic for 
T cell and antibodies in healthy European and American adult volunteers (36-40), as well as African adults, 
children, and infants (41, 42). More recently, similar adenovirus-poxvirus vectored vaccine technologies have 
been used to immunize humans against numerous other pathogens including P. vivax malaria (43), Ebola virus 
(44), hepatitis C virus (HCV) (45), respiratory syncytial virus (RSV) (46) and HIV-1 (47).
Here, we report the safety and immunogenicity of  a replication-deficient chimpanzee adenovirus sero-
type 63 (ChAd63) and an attenuated orthopoxvirus modified vaccinia virus Ankara (MVA) encoding mon-
ovalent RH5_FL based on the sequence from the 3D7 clone of  P. falciparum. These vaccines were tested in 
an open-label dose-escalation phase Ia study in healthy United Kingdom (UK) adults. These vaccines have 
been previously shown to be immunogenic in mice and rabbits (12) and exhibited significant in vivo protec-
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tion against a stringent heterologous strain blood-stage P. falciparum challenge in Aotus monkeys (34). Pro-
tection was strongly associated with anti–RH5_FL serum IgG antibody concentration and in vitro growth 
inhibition activity (GIA) measured using purified IgG (34). Now, we report that these vaccines demonstrate 
a favorable safety profile in malaria-naive adults and confirm for the first time to our knowledge that sub-
stantial RH5-specific antibodies, B cell, and T cell responses can be induced by immunization in humans. 
Vaccine-induced serum antibodies exhibited cross-strain in vitro GIA, targeted linear and conformational 
epitopes within RH5, and inhibited key interactions within the RH5 invasion complex, including those 
between RH5 and P113, CyRPA and basigin.
Results
Twenty-four healthy adult volunteers were enrolled into the VAC057 trial to assess the ChAd63-MVA RH5 vaccine in 
an open-label, dose-escalation study design. Thirty-two volunteers were screened in total, across 2 sites, and 24 
of  these were enrolled (Figure 1). Vaccinations began on August 18, 2014, and all follow-up visits were 
completed by October 28, 2015. All vaccinees received their immunizations as scheduled, and there were 
no withdrawals from the study. Similar numbers of  males and females were enrolled (13 females, 11 males). 
Figure 1. VAC057 flow chart of study design and volunteer recruitment. Enrolment into the VAC057 study began in August 2014, and all follow-up visits 
were completed by October 28, 2015. All immunizations were administered i.m. into the deltoid of the nondominant arm preferentially.
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The mean age of  volunteers was 28 years (range 19–48 years). The 4 Group 1 volunteers received 5 × 109 
viral particles (vp) of  the ChAd63 RH5 vaccine. Following a safety review, the dose of  ChAd63 RH5 was 
increased for Group 2 and volunteers received 4.26 × 1010 to 4.77 × 1010 vp (a nominal figure of  5 × 1010 vp 
is otherwise used throughout this report). Four volunteers in Group 2A received ChAd63 RH5 alone. Eight 
volunteers were enrolled into Group 2B, and a further 8 were enrolled into Group 2C. These volunteers 
received ChAd63 RH5, followed 8 weeks later with a boost vaccination of  MVA RH5 at a dose of  1 × 108 
plaque-forming units (pfu) (Group 2B) or 2 × 108 pfu (Group 2C). There was a 2-week interval between 
the final vaccination in Group 2B with MVA RH5 at the lower dose of  1 × 108 pfu and the first vaccination 
with MVA RH5 at the full dose of  2 × 108 pfu in Group 2C, with a safety review prior to dose escalation.
ChAd63 and MVA RH5 show a favorable safety profile in healthy UK adult volunteers. There were no serious 
adverse events (SAEs) or unexpected reactions and no safety concerns during the course of the trial. The reacto-
genicity of the vaccines was similar to that seen in previous malaria vaccine trials using the same viral vectors at 
similar doses in healthy adults (37, 43, 48), with the higher doses of both vaccines associated with an increased 
number and higher severity of reported AEs (Figure 2). The majority of AEs following ChAd63 RH5 were mild, 
but moderate AEs were reported by some volunteers in both groups, and 2 volunteers who received the full dose 
reported severe AEs on the day of vaccination that resolved within 24 hours. All moderate or severe solicited 
systemic AEs following MVA RH5 occurred in volunteers who had received the higher dose of vaccine. The 
Figure 2. Solicited AEs following vaccination with ChAd63 and MVA RH5. The solicited local and systemic adverse events (AEs) recorded for 7 days 
following ChAd63 RH5 and MVA RH5 are shown at the maximum severity reported by all volunteers. (A) Four volunteers received 5 × 109 viral particles (vp) 
ChAd63 RH5 (Group 1), and (B) 20 received 5 × 1010 vp (Group 2). (C) Eight of the Group 2 volunteers went on to receive MVA RH5 1 × 108 plaque-forming 
units (pfu) (Group 2B), and (D) 8 received 2 × 108 pfu (Group 2C).
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majority of solicited AEs occurred within the first 2 days after vaccination, and the median duration of each 
systemic AE was between 1 and 2 days following either vaccine. The unsolicited AEs considered possibly, prob-
ably, or definitely related to either vaccine are shown in Supplemental Table 1 (supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.96381DS1). The majority were mild in nature, and 
all resolved spontaneously. There were no severe laboratory AEs following ChAd63/MVA RH5 vaccination. 
One volunteer had a moderately raised ALT (123 IU/l) at day 7 (d7) following ChAd63 RH5 that had resolved 
fully by d28. One volunteer had moderate thrombocytopenia (123 × 109/l) and mild leukopenia (3.3 × 109/l) 
at d28 following ChAd63 RH5 but had commenced postexposure prophylaxis for a possible HIV exposure the 
day before these bloods were taken; therefore, causality is unclear. All other laboratory AEs were mild and had 
resolved fully by d84, except for 1 volunteer who had a persistent mild anemia. This had been present at screen-
ing and had not worsened over the course of the study, so it was not considered significant.
ChAd63 and MVA RH5 expand IFN-Ȗ T cell responses in healthy UK adult volunteers. The kinetics and mag-
nitude of  the RH5-specific T cell response were assessed over time by ex vivo IFN-Ȗ ELISPOT following 
restimulation of  PBMC with 20-mer peptides overlapping by 10 amino acids (aa) spanning the entire 
RH5 insert present in the vaccines (Figure 3 and Supplemental Table 2). Vaccination with ChAd63-
MVA RH5 induced antigen-specific T cell responses in all volunteers, with individual responses shown in 
Supplemental Figure 1 and median responses to the total vaccine insert shown for each group in Figure 
3A. Following ChAd63 RH5 prime, there was no significant difference between median responses in the 
lower-dose Group 1 in comparison with Group 2 at the peak of  the response on d14 (median 499 [range 
96–993] vs. 797 [range 3–3,269] spot forming units [SFU]/million PBMC in Groups 1 vs. 2 respectively 
[n = 4 vs. 20, P = 0.27 by Mann-Whitney test]) (Figure 3B). Responses subsequently followed classical T 
cell kinetics and contracted by d56 (Figure 3A). Administration of  MVA RH5 significantly boosted these 
responses in all volunteers as measured 1 week later on d63 (Groups 2B and 2C vs. 2A, Kruskal-Wallis 
test with Dunn’s multiple comparison test) (Figure 3C), reaching medians of  2092 [range 628–4,102] and 
2,281 [range 935–4,257] SFU/million PBMC in Groups 2B and 2C, respectively, vs. 213 [range 15–363] 
SFU/million PBMC in Group 2A. However, there was no significant difference between the 2 groups 
who received the different doses of  MVA RH5 (P = 0.33, Mann-Whitney test). T cell responses were 
detected in all 6 of  the peptide pools used in the ELISPOT assay (Supplemental Figure 2), confirming 
these were spread across the whole RH5_FL antigen, and thus including both structured and disordered 
regions of  the molecule (49, 50). Following the peak at d63, responses contracted and were maintained 
above baseline at the end of  the study period, again with no significant difference between Groups 2B 
and 2C (P = 0.27, Mann-Whitney test) (Figure 3D).
ChAd63 and MVA RH5 induce serum antibody responses and memory B cells (mBCs) in healthy UK adult 
volunteers. The kinetics and magnitude of  the anti-RH5 serum IgG antibody response were assessed over 
time by ELISA against RH5_FL recombinant protein (Figure 4). Priming vaccination with 5 × 1010 vp 
ChAd63 RH5 followed by MVA RH5 boost induced antigen-specific IgG responses in all volunteers 
(Groups 2B and 2C), with individual responses shown in Supplemental Figure 3 and median responses 
shown for each group in Figure 4A. Responses are reported in ȝg/ml following conversion of  ELISA 
arbitrary units (AU) by calibration-free concentration analysis (CFCA) (Supplemental Figure 4). Fol-
lowing ChAd63 RH5 prime with 5 × 109 vp, 2 of  4 volunteers showed a detectable response on d28, in 
contrast to 16 of  20 volunteers (median: 0.2, range: 0–2.3 ȝg/ml, n = 20) following priming with 5 × 
1010 vp (P = 0.13, Mann-Whitney test) (Figure 4B). Responses were subsequently maintained in Group 
2 volunteers prior to administration of  MVA RH5, which led to a boost as measured 4 weeks later on 
d84 (Figure 4A); this reached significance for Group 2C vs. 2A (P = 0.008, Kruskal-Wallis test with 
Dunn’s multiple comparison test) (Figure 4B). Responses in Group 2C (median: 9.3, range: 0.5–14.5 ȝg/
ml, n = 8) tended to be higher than in Group 2B, but this did not reach significance (median: 4.0, range: 
2.1–17.5 ȝg/ml, n = 8) at this peak time point (P = 0.33, Mann-Whitney test). Serum antibody responses 
decreased by d140 but were well maintained above preboost levels, with significance of  Group 2C over 
2A (P = 0.005, Kruskal-Wallis test with Dunn’s multiple comparison test) (Figure 4B). We also compared 
postboost responses induced by the vaccine (Groups 2B and 2C combined) with those induced by natural 
malaria exposure in 79 Ghanaian adults and 96 Kenyan adults (Figure 4C). Anti-RH5_FL IgG responses 
were weak in the malaria-endemic populations, with median responses less than 0.1 ȝg/ml in both and 
the highest 4 ȝg/ml in a single Kenyan adult. The vaccine-induced responses were significantly higher (P 
< 0.0001, Kruskal-Wallis test with Dunn’s multiple comparison test).
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The vaccine-induced serum antibody response against RH5_FL as measured by ELISA at d84 was 
composed of  IgG1 and moderate levels of  IgG3 (Figure 4D) with little to no IgG2 or IgG4 (Supplemental 
Figure 5A). Low levels of  IgA and IgM were detectable above baseline (d0) levels in only a few volunteers 
(Supplemental Figure 5A). This profile was maintained at the end of  the study period (d140); however, 
responses were measured at lower levels, consistent with the anti-RH5_FL total IgG ELISA kinetic (Sup-
plemental Figure 5B). The avidity of  the anti–RH5_FL IgG, as measured by a sodium thiocyanate dis-
placement (NaSCN displacement) ELISA, was similar at d84 for all volunteers in Groups 2A, 2B, and 2C, 
with the IC
50
 (concentration of  NaSCN required to reduce the starting OD in the ELISA by 50%) ranging 
from 0.8 to 1.7 M. Avidity showed a significant increase in Groups 2B and 2C from d28 to d84 (n = 16, P = 
0.001, Wilcoxon matched-pairs signed rank test); however, the same trend was observed in Group 2A (n = 
2), suggesting that this may relate to IgG affinity maturation over time, as opposed to a direct consequence 
of  MVA RH5 boost (Figure 4E).
Previous studies have shown that antibody-secreting cells (ASC) can be detected in peripheral blood 
for a short time (around d7) after MVA boost when using the ChAd63-MVA regimen (51, 52). RH5_FL–
specific ASC responses were assessed by ex vivo ELISPOT using fresh PBMC collected at the d63 visit 
for volunteers in Groups 2B and 2C. Median responses of  52 vs. 180 RH5_FL–specific ASC per million 
PBMC were observed, respectively, but there was no significant difference between the 2 groups (P = 0.15, 
Mann-Whitney test) (Figure 5A). ASC responses across both groups showed a significant correlation, with 
peak serum antibody responses at d84 (Figure 5B).
Figure 3. Ex vivo IFN-Ȗ T cell response to vaccination. (A) Median ex vivo IFN-Ȗ enzyme-linked immunospot (ELISPOT) responses in peripheral blood mononu-
clear cells (PBMC) to the RH5 insert (summed response across all the individual peptide pools) shown for all groups. Individual responses are shown in Supple-
mental Figure 1. Median and individual responses are shown at (B) d14 (n = 4 vs. 20); (C) d63 (G2A, n = 4; G2B, n = 8; G2C, n = 8) assessed by Kruskal-Wallis test 
with Dunn’s multiple comparison test; and (D) d140 (G2A n = 4, G2B n = 8, G2C n = 8). Symbols are coded according to group. *P < 0.05, **P < 0.01.
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Figure 4. Serum antibody response to vaccination. Group 1 (n = 4), Group 2A (n = 4), Group 2B (n = 8), Group 2C (n = 8). (A) Median anti–RH5_FL 
serum total IgG responses shown for all groups over time. Individual responses are shown in Supplemental Figure 3. Median and individual responses 
are shown at (B) d28, d84, and d140. The horizontal dotted line indicates the limit of detection of the assay. Statistical analysis using Kruskal-Wallis 
test with Dunn’s multiple comparison test. (C) Vaccine-induced responses shown for Groups 2B and 2C combined (n = 16) vs. responses following 
natural exposure in Ghanaian adults (n = 79) and Kenyan adults (n = 96); analysis by Kruskal-Wallis test with Dunn’s multiple comparison test. (D) 
Isotype proiles of serum antibody responses against RH5_FL were assessed by ELISA. Responses are shown at baseline (d0) and for all groups at 
d84. Individual and median responses are shown for IgG1 and IgG3; results for IgG2, IgG4, IgA, and IgM are shown in Supplemental Figure 5. (E) Avid-
ity of serum IgG responses at d28 and d84 was assessed by sodium thiocyanate (NaSCN) displacement RH5_FL ELISA and is reported as the molar 
(M) concentration of NaSCN required to reduce the starting OD in the ELISA by 50% (IC
50
). Only samples with a positive response by anti–RH5_FL 
total IgG ELISA could be assayed for avidity. Symbols are coded according to group. *P < 0.05, **P < 0.01, ****P < 0.0001.
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mBC responses were also measured using an established cultured ELISPOT protocol, whereby mBC 
within PBMC undergo a 6-day polyclonal stimulation to form ASC, which are then measured using the 
same protocol as for the ex vivo assay. These were measured for volunteers in Groups 2B and 2C at the 
d84 and d140 time points (4 and 12 weeks after MVA boost). D84 was most consistently identified as the 
peak of  the mBC response in other trials of  ChAd63-MVA P. falciparum blood-stage malaria vaccines (51, 
52). Responses are reported as number of  mBC-derived RH5-specific ASC per million cultured PBMC 
(Figure 5C), and as a percentage of  total IgG-secreting ASC (Figure 5D). The d84 mBC responses across 
both groups did not correlate with peak serum antibody responses at d84 (data not shown). Overall, there 
were no significant differences between the groups or time points, indicating the mBC response was well 
maintained to the end of  the study period.
Vaccine-induced antibodies show cross strain in vitro GIA. Serum was analyzed at the GIA Reference 
Center at NIH, with IgG purified from each sample prior to initial testing against vaccine homologous 
3D7 clone parasites. Baseline samples prior to vaccination (d0) using pooled sera, as well as individual 
samples from Groups 1 and 2A from d84 after vaccination, did not demonstrate any GIA above baseline. 
Samples from Group 2B and 2C volunteers taken at d84 showed in vitro GIA of  median 36.0% (range 
19.7%–61.6%) and 50.6% (range 7.2%–68.1 %) using 10 mg/ml purified IgG (Figure 6A). We confirmed 
Figure 5. B cell response to vaccination. (A) RH5-speciic antibody-secreting cell (ASC) responses were assessed by ex vivo enzyme-linked immunospot 
(ELISPOT) using RH5_FL protein and fresh peripheral blood mononuclear cells (PBMC) from the d63 time point. Individual and median responses are 
shown for each group and reported as RH5-speciic ASC per million PBMC used in the assay (n = 8 for Group 2B and n = 7 for Group 2C because 1 sample 
was not tested in this group). (B) Correlation of the ASC response vs. the concentrations of serum anti–RH5_FL IgG measured at d84. Spearman’s rank 
correlation coeicient (r
s
) and P value are shown by Spearman’s rank correlation. (C) RH5-speciic memory B cell (mBC) responses were assessed by ELIS-
POT assay using RH5_FL protein (n = 8 for Groups 2B and 2C). Frozen PBMC were thawed and underwent a 6-day polyclonal restimulation, during which 
ASC are derived from mBC, before testing in the assay. Individual and median responses are shown from the d84 and 140 time points and are reported as 
mBC-derived RH5-speciic ASC per million cultured PBMC or as (D) % of total number IgG-secreting ASC (n = 7 for Group 2C at the d140 time point in D, 
otherwise n = 8). Groups 2B and 2C are coded by color and symbol.
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that GIA decreased as purified IgG was diluted in the assay (Figure 6B) and also that GIA was not 
enhanced by inclusion of  complement (Supplemental Figure 6). The GIA (as routinely assessed, without 
complement) was related to RH5_FL–specific IgG concentration (Figure 6C), as seen for the merozoite 
surface protein 1 (MSP1) and apical membrane antigen 1 (AMA1) antigens following human immuniza-
tion (9, 52, 53). Notably, the concentration of  anti-RH5_FL polyclonal IgG that gives 50% GIA (EC
50
) 
was only 8.2 ȝg/ml. Two volunteers also consistently showed a better quality of  response, with a 2.5-fold 
improvement in the EC
50
 (3.3 ȝg/ml RH5_FL–specific IgG) against the 3D7 clone parasite, although 
no other obvious differences were apparent in their antibody profile, as measured by the various ELISA 
assays. This EC
50
 concentration is substantially lower than previous results with vaccines against the 
AMA1 and MSP1 antigens (9, 52, 53). In line with this result, the overall levels of  GIA using 10 mg/
ml purified IgG from these RH5 vaccinees against 3D7 clone parasites were higher than those achieved 
with the same ChAd63-MVA platform used previously to deliver AMA1 or MSP1 (54), reaching signif-
icance for MSP1 (P = 0.02, Kruskal-Wallis test with Dunn’s multiple comparison test comparing RH5 
with AMA1 and MSP1) (Supplemental Figure 7A). However, the levels of  GIA using 10 and 2.5 mg/ml 
purified IgG against 3D7 clone parasites were comparable with those reported previously in healthy UK 
adults immunized with an AMA1 recombinant protein vaccine delivered in the proprietary adjuvant sys-
Figure 6. Functional GIA induced by ChAd63-MVA RH5 vaccination. (A) In vitro growth inhibition activity (GIA) of puriied IgG was assessed at 10 mg/ml 
against 3D7 clone P. falciparum parasites. Individual data and medians are shown for each group at d84 (G1, n = 4; G2A, n = 4; G2B, n = 8; G2C, n = 8); pooled 
sera were used for each group (n = 4) at baseline (d0). (B) Dilution series of puriied IgG from Group 2B and 2C d84 samples. (C) Relationship between GIA 
data from the dilution series shown in B and concentration of anti–RH5_FL puriied IgG used in the assay as measured by ELISA. The EC
50
 (concentration 
of anti-RH5_FL polyclonal IgG that gives 50% GIA, dashed line) was 8.2 ȝg/ml (95% CI, 7.2–9.5 ȝg/ml); nonlinear regression curve is shown (solid line, r2 = 
0.90, n = 74). Two volunteers (1 in Group 2B and 1 in 2C) showed a reproducibly higher EC
50
 of 3.3 ȝg/ml (95% CI, 2.8–3.9 ȝg/ml); nonlinear regression curve is 
shown (dotted line, r2 = 0.99, n = 10). (D) Puriied IgG from Group 2B and 2C d84 samples, plus 1 pooled d0 preimmunization sample, were tested at 10 mg/
ml against a panel of 8 other laboratory-adapted parasite lines and short-term culture-adapted parasite isolates. GIA for each parasite and test sample is 
plotted against corresponding GIA against 3D7 clone parasites on the x axis.
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Figure 7. Vaccine-induced anti-RH5 antibodies recognize linear epitopes and RH5Nt. (A) D0 and d84 sera for volunteers in Groups 2B and 2C (n = 
16) were diluted 1:100 and tested against linear overlapping peptides spanning the RH5 vaccine insert. Median, interquartile range (IQR), and range 
are shown for each peptide. (B) Plot of disorder within the RH5 vaccine construct predicted by PONDR. Blue arrows indicate the regions removed in 
the RH5ǻNL protein (E26-Y139 and N248-M296). (C) D0 and d84 sera for volunteers in Groups 2B (green triangles) and 2C (purple triangles) (n = 16) 
were diluted 1:100 and tested against 19-mer peptides that represent the minimal P113 binding region within RH5Nt (K33-K51). Peptides with N- and 
C-terminal biotinylation were tested to allow for binding to streptavidin-coated plated in both orientations. Individual and median results are shown. 
(D) D0 and d84 sera for volunteers in Groups 2B and 2C were diluted 1:100 and tested against RH5Nt protein. Individual and median results are shown 
(n = 16). (E) Correlation of d84 serum IgG responses in Groups 2B and 2C (n = 16) against RH5_FL and RH5Nt. Spearman’s rank correlation coeicient 
(r
s
) and P value are shown by Spearman’s rank correlation.
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tem AS01B from GSK (P = 0.16 and P = 0.78, respectively, Mann-Whitney test) (ref. 53 and Supplemen-
tal Figure 7, A and B). This relates to the fact that the AMA1/AS01B formulation was quantitatively 10 
times more immunogenic, achieving approximately 100 ȝg/ml AMA1-specific IgG on average in these 
vaccinees (53), unlike the 9.3 ȝg/ml RH5_FL–specific IgG measured on average in Group 2C.
We next assessed the purified IgG from Groups 2B and 2C against a panel of  8 other laboratory-adapted 
parasite lines (7G8, Dd2, FVO, GB4, MCamp) and short-term culture-adapted parasite isolates (from Cam-
bodian patients with malaria [Cp845, Cp806; ref. 18] or from an Australian resident who contracted malaria 
in Ghana [HMP002; ref. 55]), that between them include RH5 sequences that encompass the 5 most common 
RH5 single nucleotide polymorphisms (SNPs) (18, 19). All parasites were neutralized by the IgG, with results 
for each parasite significantly correlating with 3D7 (n = 16, P < 0.0001 and Spearman’s rank correlation 
coefficient [r
s
] > 0.88 for all parasites) (Figure 6D). Notably, %GIA against 1 parasite was significantly low-
er: Cp806 (P = 0.0001); while 2 strains showed significantly higher %GIA: FVO (P = 0.029) and GB4 (P = 
0.0009) by Friedman test with Dunn’s multiple comparison test.
Vaccine-induced antibodies recognize linear and conformational epitopes and inhibit interactions within the RH5 
complex. We next sought to better understand the fine specificity of  the vaccine-induced anti-RH5 antibody 
response. We initially tested the d84 sera from all volunteers in Groups 2B and 2C by ELISA against a lin-
ear peptide array spanning the RH5_FL vaccine sequence (Supplemental Table 3 and Figure 7A). Respons-
es were detected to the N-terminal region, as well as a central region and a small part of  the C-terminus, 
suggesting the vaccine-induced anti–RH5_FL IgG do recognize linear epitopes within the RH5 molecule. 
Interestingly, these responses to linear epitopes mainly correspond to predicted regions of  disorder within 
the RH5 molecule (Figure 7B). Further analysis of  the peptide data highlighted peptide 28 — against which 
the sera from all 16 volunteers reacted— which is also recognized by the nonneutralizing mouse mAb 4BA7 
(56), as well as peptide 5 in RH5Nt, which is recognized by the nonneutralizing mouse mAb RB3 (56). Other 
peptides of  interest include peptides 1–3 within RH5Nt, given that the P113-binding region was previously 
mapped to a 19-mer sequence running from aa K33–K51 (29). These peptide reagents included the N38Q aa 
substitution in the vaccine construct to remove a site of  potential N-linked glycosylation. We therefore syn-
thesized the native 19-mer sequence, biotinylated at either the N- or the C-terminus (Supplemental Table 3), 
and assessed responses by ELISA (Figure 7C). Similar to the results with the original peptide 2, all volunteers 
showed detectable responses irrespective of  bound peptide orientation. We also confirmed these results using 
recombinant RH5Nt protein in ELISA (Figure 7D), and these data would suggest the sera have the potential 
to inhibit the RH5Nt-P113 interaction. Notably, these responses to RH5Nt significantly correlated with those 
against RH5_FL (Figure 7E), suggesting that in each vaccinee, the response to RH5Nt is a consistent propor-
tion of  the total anti–RH5_FL response irrespective of  overall magnitude.
To assess whether responses are also directed against conformational epitopes, we next performed 
ELISA against heat-denatured RH5_FL protein (Figure 8A). These data showed significant loss of  
sero-reactivity in all vaccinees (P = 0.008 for both groups by Wilcoxon matched-pairs signed rank test) 
— similar to the conformation-sensitive mAb 2AC7 (49, 56), but not mAb 4BA7, which binds a linear 
peptide (56). To investigate further, we performed ELISA using RH5ǻNL protein, which lacks the 
disordered N-terminal and central loop regions of  RH5 (49), and quantified these responses by CFCA. 
Responses to this protein were concordant with those against RH5_FL (Figure 8B), suggesting that 
most of  the vaccine-induced IgG recognize the RH5ǻNL structured protein and that the linear peptide 
array and RH5Nt ELISA are measuring only a minor proportion of  the total anti–RH5_FL response.
We next assayed the ability of  these sera to inhibit interactions within the RH5 complex by avidi-
ty-based extracellular protein interaction screen (AVEXIS). These data confirmed that the d84 sera from 
the Groups 2B and 2C volunteers could inhibit the interaction between RH5 and P113, as well as RH5 and 
basigin and RH5 and CyRPA (Figure 9A). One volunteer in Group 2C showed no inhibition, consistent 
with their very low postboost anti–RH5_FL IgG concentration (Supplemental Figure 3D). Notably, the 
blocking activity observed by AVEXIS for each of  the 3 interactions significantly correlated with the anti–
RH5_FL IgG response (Figure 9B).
Discussion
This phase Ia dose escalation and safety clinical trial reports the first data to our knowledge in humans 
for a vaccine targeting the RH5 antigen from the blood-stage P. falciparum merozoite. We show in healthy 
malaria-naive UK adult volunteers that a recombinant ChAd63-MVA heterologous prime-boost immu-
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nization regimen has a favorable safety profile and can induce functional RH5-specific–serum antibody 
responses, in addition to B and T cell responses. Reactogenicity of  the ChAd63 RH5 vector was similar to 
that seen with the same doses of  ChAd63 vectored vaccines encoding the P. falciparum antigen multiepitope 
string-thrombospondin-related adhesion protein (ME-TRAP), circumsporozoite protein (CSP), MSP1, or 
AMA1 (36–39, 52, 54) or the P. vivax antigen Duffy-binding protein region II (PvDBP_RII) (43). The 
same vectors encoding ME-TRAP have similarly been safe following immunization of  adults, children, and 
infants residing in malaria-endemic areas (41, 42). Our data with ChAd63 RH5 add to the growing body of  
evidence that this simian adenovirus vector is safe for clinical use. Likewise, the clinical safety of  MVA as 
a recombinant vaccine vector for many infectious diseases and cancer is now well documented (57). MVA 
RH5 appeared to be more reactogenic than the ChAd63 vector at the higher dose, consistent with previous 
vaccine trials using this orthopoxvirus vector (38, 39, 43, 44, 46, 58).
The ChAd63 and MVA vectors used here were designed to maximize induction of  antibody responses 
against blood-stage malaria antigens, in conjunction with the T cell responses for which they are more rou-
tinely used (32, 33). In this trial, RH5-specific IFN-Ȗ T cell responses were induced and peaked following the 
MVA boost at median levels of  > 2,000 SFU/million PBMC. No data on cellular responses to this antigen 
have been reported following natural P. falciparum infection; however, given that vaccination elicited pep-
tide-restimulated responses spanning the entire RH5 sequence, the RH5_FL molecule does not appear to lack 
T cell epitopes. The kinetics and magnitude of  the response were also similar to those previously reported 
following human vaccination with the same vectors encoding P. falciparum or P. vivax antigens (36–39, 43). 
Similarly, studies using chimpanzee adenovirus vectors followed by MVA boost (44, 46, 58) have routinely 
shown that a mixed antigen–specific CD4+/CD8+ T cell response is induced in humans. The possible contri-
bution of  T cells to blood-stage malaria protection remains unclear, given that previous clinical trials using 
whole parasite immunization (59) or ChAd63-MVA vectors encoding MSP1 or AMA1 (54) failed to show 
an impact on blood-stage parasite growth following controlled human malaria infection (CHMI) with P. fal-
ciparum despite strong T cell induction by vaccination. However, CD8+ T cells against blood-stage antigens 
can act against late liver-stage forms of  the parasite once merozoite antigens are expressed (54, 60), while viral 
vector vaccine-induced CD4+ T cells will provide key help to B cell responses (61, 62).
In agreement with preclinical data in mice, rabbits, and Aotus monkeys (12, 34), the ChAd63-MVA 
RH5 vaccines induced RH5_FL–specific serum IgG antibody responses, peaking at a median of  0.2 ȝg/
ml after ChAd63 prime and 9.3 ȝg/ml after MVA boost in the full-dose vaccination Group 2C. The overall 
kinetic and magnitude of  the RH5_FL–specific IgG, ASC, and mBC responses induced here in malaria-na-
ive humans are broadly comparable with those reported for the same vectors encoding PvDBP_RII (43) or 
P. falciparum MSP1 and AMA1 (38, 39, 51, 52). These vaccine-induced RH5_FL–specific IgG concentra-
Figure 8. Vaccine-induced antibodies recognize conformational epitopes and inhibit interactions within the RH5 
invasion complex. (A) D0 and d84 sera for volunteers in Groups 2B and 2C (n = 16) were tested by ELISA against non-
denatured RH5_FL protein (–) and the same protein following heat denaturation (+). Individual and median responses 
are shown. The 4BA7 and 2AC7 mAbs were included as controls that bind a linear vs. conformational epitope, respec-
tively. **P < 0.01 according to Wilcoxon matched-pairs signed rank test. (B) D84 serum ELISA responses to RH5_FL and 
RH5ǻNL for volunteers in Groups 2B and 2C (n = 16) were analyzed for concordance by linear regression (solid line). r2 = 
0.69; slope = 0.91 (95% CI, 0.56–1.27); Y intercept when X = 0.0 is 0.4 (95% CI, –2.7–3.6); X intercept when Y = 0.0 is –0.5 
(95% CI, –6.0–2.3). Line of identity (X=Y) is also shown (dashed line).
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Figure 9. Vaccine-induced antibodies inhibit interactions within the RH5 invasion complex. (A) D0 and d84 Group 2B sera (n = 7) and Group 2C 
sera (n = 8) were tested for their ability to inhibit the interaction between proteins from the RH5 invasion complex by AVEXIS. Dilution of each test 
serum sample is shown starting at 1:10. Results with various assay controls also shown (no serum for RH5-Basigin, and anti-AMA1 for RH5-CyRPA 
and RH5-P113). Each point represents the mean of duplicate or triplicate wells. (B) Correlation of blocking activity for each interaction using d84 
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tions are similar to those observed following ChAd63-MVA immunization with PvDBP_RII (43) but are 
lower than P. falciparum AMA1 (38, 52) and MSP1 (38) and higher than CSP (37). Notably, in agreement 
with immunoepidemiological datasets (12, 23–26), anti–RH5_FL IgG responses were weak in the Kenyan 
and Ghanaian adult populations assessed here for comparison, with median responses < 100 ng/ml. The 
vaccine data, thus, confirm that RH5 is not in itself  a weakly immunogenic antigen in humans but instead 
suffers modest immunogenicity in the context of  natural P. falciparum infection.
Consistent with other ChAd63-MVA malaria vaccines (43, 52, 63), the anti–RH5_FL serum IgG 
response was largely composed of  IgG1 and IgG3, with moderate avidity as measured by NaSCN displace-
ment ELISA. A study of  naturally exposed individuals in Mali reported that the predominant IgG isotype 
detected against RH5 was IgG3 (23). A similar result was observed in children from Papua New Guinea 
(64), suggesting qualitative aspects of  the vaccine-induced response may differ to those induced by natural 
exposure. Overall, the relevance of  antibody isotype, affinity, and avidity to in vivo protection in humans 
against the P. falciparum merozoite remain debated, although the study in Papua New Guinea associated 
the IgG3 response against RH5 with reduced risk of  malaria (64).
We subsequently assessed the functional anti-parasitic antibody activity using the standardized in vitro 
assay of  GIA. In agreement with preclinical studies, these data confirmed the vaccine-induced antibodies in 
humans were strain transcending, showing activity against all tested parasites. Notably, addition of  human 
complement did not increase levels of  GIA, as reported for some merozoite surface proteins (65). This is 
perhaps not surprising, given that antibodies only have a very short window of opportunity to bind RH5 fol-
lowing its release from the rhoptries, likely leading to time constraints on complement recruitment. Notably, 
some individual parasite laboratory lines or short-term culture-adapted parasite isolates significantly differed 
in their sensitivity to neutralization in comparison with the 3D7 reference clone — with 2 being easier to neu-
tralize and 1 less so. The reasons for these differences remain to be investigated. The panel of  parasites used 
here covered a significant breadth of  the known RH5 sequence diversity (18, 19, 21), encompassing at least 8 
catalogued nonsynonymous SNPs, including the top fifth and seventh most common SNPs by global minor 
allele frequency (MAF) at positions 148, 147, 197, 203, 410, and 407 (MalariaGEN v4.0, ref. 66). A previous 
rabbit study using the same parasite isolates from Cambodian patients showed a similar range of  susceptibility 
to vaccine-induced anti–RH5_FL IgG (18), which was not associated with the presence of  small numbers of  
specific polymorphisms. It remains likely that other aspects of  the RH5 invasion complex biology can affect 
the susceptibility of  individual parasite isolates to anti-RH5 antibodies.
Most encouragingly, the GIA EC
50
 concentration of  RH5_FL–specific polyclonal human IgG against 
3D7 clone parasites was only 8 ȝg/ml. A previous study affinity-purified RH5-specific human IgG from plas-
ma of  naturally exposed individuals in Mali and tested for GIA, reporting an EC
50
 concentration of  55 ȝg/
ml (23), which suggests the vaccine-induced IgG here may be qualitatively superior to the responses induced 
against RH5 following natural parasite exposure. Moreover, this level is substantially lower than previous 
results with vaccines tested in humans against the AMA1 and MSP1 antigens, where GIA EC
50
 concen-
trations were reported from 70–100 ȝg/ml (9, 52, 53) and > 600 ȝg/ml (9) for AMA1- and MSP1-specific 
human IgG, respectively. Consequently, the levels of  GIA observed here with ChAd63-MVA RH5 outper-
formed those previously observed in humans with the same vectors encoding MSP1 or AMA1 (54), given that 
these vaccines all induce quantitatively similar levels of  IgG. Our data, thus, identify a clear hierarchy, where-
by the RH5 antigen is inherently more susceptible to vaccine-induced human IgG than the historically favored 
AMA1 and MSP1 target antigens — consistent with preclinical data in rabbits (18) and in vivo protection data 
in Aotus monkeys (34), boding well for future efficacy testing of  RH5-based vaccines.
Finally, we further sought to better understand the breadth of  epitopes recognized by anti–RH5_FL 
IgG. We initially identified regions of  linear antibody epitopes within the RH5_FL molecule by peptide 
array, including the disordered N-terminus and internal loop between helices 2 and 3 (49). Mouse mAbs 
that bind linear peptides within both of  these regions have been shown to be nonneutralizing (56); however, 
immunization data with RH5Nt (29) and another mAb study (67) suggest the N-terminal region of  the 
molecule can elicit functional antibodies that may block P113 binding and/or interfere with proteolytic pro-
sera from Groups 2B and 2C (n = 15) against anti–RH5_FL serum IgG responses measured by ELISA. Blocking activity was calculated for each individ-
ual sample from the data in panel A as the ratio of the Abs 485 nm at 1:10 serum dilution divided by the Abs 485 nm at the highest serum dilution 
tested. Spearman’s rank correlation coefficient (r
s
) and P value(Spearman’s rank correlation) are shown.
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cessing of  RH5_FL. Further analysis confirmed the vaccine-induced IgG also recognized conformational 
epitopes. Quantitative assessment by ELISA and CFCA using the structured RH5ǻNL protein (which 
lacks the disordered N-terminus and internal loop) suggested that most of  vaccine-induced IgG recognize 
this region of  RH5 and that antibodies against RH5Nt constitute only a minor, but consistent, proportion 
of  the total anti–RH5_FL response. Subsequent testing by AVEXIS confirmed the sera from vaccinees 
could block the interaction of  RH5_FL with P113, CyRPA, and basigin, consistent with known infor-
mation relating to the binding of  these molecules (29, 49, 56, 68) and the measurable antibody responses 
against both RH5Nt and RH5ǻNL. Interestingly, blocking activity for all 3 interactions correlated with the 
anti–RH5_FL IgG response, suggesting qualitatively similar responses were induced in all vaccinees. Our 
ongoing work will focus on elucidating epitopes recognized by vaccine-induced human B cells in order to 
guide future immunomonitoring and better understand mechanisms of  P. falciparum merozoite neutraliza-
tion and inhibition of  these interactions within the complex.
Overall, substantial progress has been made since RH5_FL was first reported as a promising new vac-
cine candidate in late 2011. Here, we demonstrate for the first time to our knowledge, using a rapidly trans-
lated viral vectored vaccine platform, that substantial RH5_FL–specific antibodies and B cell and T cell 
responses can be induced safely by immunization in humans, in contrast to the levels of  responses observed 
following years of  natural malaria exposure. Our recent demonstration of  a blood-stage CHMI model for 
vaccine testing using P. falciparum (53) will allow for rapid phase IIa proof-of-concept efficacy testing of  
RH5-based vaccines in the near future.
Methods
Detailed methods are provided in Supplemental Methods.
ChAd63 and MVA RH5 vaccines. The design, production, and preclinical testing of  the viral vector vac-
cines have been reported previously in detail (12, 34). Briefly, both recombinant viruses express the same 
1,503 bp coding sequence of  RH5 from the 3D7 clone of  P. falciparum, aa E26–Q526 (NCBI accession 
number XM_001351508.1). ChAd63 RH5 was manufactured by Advent, which is a daughter company 
of  ReiThera. This production facility meets current Good Manufacturing Practice (cGMP) requirements 
of  the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to produce 
investigational vaccines to be used in human clinical studies. MVA RH5 was manufactured under cGMP 
conditions by IDT Biologika GmbH, Germany, as previously described (38).
Study design. VAC057 was a first-in-human, open-label, nonrandomized, dose-escalation phase Ia clin-
ical trial evaluating the safety and immunogenicity of  the viral vectored vaccines ChAd63 RH5 and MVA 
RH5 in a heterologous prime-boost regime with an 8-week interval. The study was conducted in the UK 
at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM; University of  Oxford, Oxford, 
United Kingdom) and the NIHR Wellcome Trust Clinical Research Facility (WTCRF) in Southampton, 
UK. The trial was registered on Clinicaltrials.gov (NCT02181088). The primary endpoint of  the study was 
to assess the safety of  ChAd63 RH5 and MVA RH5, with a secondary endpoint to assess immunogenicity.
Participants. Healthy, malaria-naive males and nonpregnant females aged 18–50 were invited to partici-
pate in the study. Volunteers were recruited and vaccinated at the CCVTM, part of  the Oxford Vaccine Centre 
(OVC), at the University of  Oxford and the NIHR WTCRF in Southampton. Twenty-four volunteers were 
enrolled in total. A full list of  inclusion and exclusion criteria is reported in Supplemental Methods.
Safety analysis. Following each vaccination, volunteers completed an electronic diary card for 28 days 
with any AE data. AE data were also collected at follow-up visits. Observations (heart rate, temperature, 
and blood measures) were taken at the clinic visits from the day of  vaccination until the d28 follow-up visit. 
Blood tests for exploratory immunology were taken at all visits except those occurring 2 days after each vac-
cination (i.e., d2 and d58). Blood samples for safety (full blood count, liver function, urea, and electrolytes) 
were carried out at screening, d0, d7, and d28 for all groups, as well as on d56, d63, and d84 for Groups 2B 
and 2C. Any solicited AEs occurring during the diary card period were defined as being at least possibly 
related to vaccination. The likely causality of  all other AEs was assessed as described in the protocol, and 
all AEs considered possibly, probably, or definitely related to vaccination are reported (Supplemental Table 
1). Further details on grading are provided in the Supplemental Material.
Peptides. Peptides for ex vivo IFN-Ȗ ELISPOT and the K33-K51 ELISA peptides were purchased from 
NEO Scientific (Supplemental Table 2), while the biotinylated overlapping 20-mer peptides for ELISA 
were synthesized by Mimotopes (Supplemental Table 3).
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Recombinant RH5 proteins for ELISAs and B cell assays. Recombinant RH5_FL and RH5ǻNL proteins 
were generated using Drosophila melanogaster Schneider 2 (S2) polyclonal stable cell lines (ExpreS2 platform, 
ExpreS2ion Biotechnologies) (69), while RH5Nt protein was produced using HEK293-6E cells as previous-
ly described (29).
Ex vivo IFN-Ȗ ELISPOT. Ex vivo IFN-Ȗ ELISPOT was used to assess the kinetics and magnitude of  
the vaccine-induced T cell responses over time. Fresh PBMC were used in all assays using a previously 
described protocol (39). Results are expressed as IFN-Ȗ SFU per million PBMC.
Total IgG ELISAs. ELISAs were performed using standardized methodology as previously described 
(38, 39), except that plates were coated with recombinant RH5_FL or RH5ǻNL protein produced from the 
Drosophila S2 cells. Responses measured in AU are reported in ȝg/ml following generation of  a conversion 
factor by calibration-free concentration analysis (CFCA).
Avidity and isotype ELISAs. IgG antibody avidity was assessed by NaSCN displacement ELISA using 
previously described methodology (63), except that plates were coated with recombinant RH5_FL pro-
duced from the Drosophila S2 cells at 2 ȝg/ml. The concentration of  NaSCN required to reduce the OD
405
 
(optical density measured at 405 nm)to 50% of  that without NaSCN was used as a measure of  avidity 
(IC
50
). Antibody isotype ELISAs were also performed using methodology described in detail elsewhere (63) 
with the same exception as for the avidity ELISA.
mBC and ASC ELISPOT. mBC ELISPOT assays using RH5_FL protein were performed as described in 
detail elsewhere (51). Ex vivo ASC ELISPOT assays were performed using fresh PBMC directly prepared 
and added to the ELISPOT plate with no preceding 6-day culture.
Assay of  GIA. The ability of  antibodies to inhibit growth of  P. falciparum parasites in vitro was assessed 
at the GIA Reference Center (NIAID, NIH) as previously described (70). All samples were tested at 10 mg/
ml in a final test well, followed by a dilution series for positive samples to determine the concentration that 
gave 50% GIA (EC
50
). Serum IgG concentrations were measured using HPLC.
AVEXIS. AVEXIS was performed essentially as described (71) using d0 and d84 serum. Controls 
included addition of  no serum or addition of  polyclonal rabbit IgG raised against AMA1 (19).
Statistics. Data were analyzed using GraphPad Prism version 6.07 for Windows (GraphPad Software 
Inc.). All tests used were 2-tailed and are described in the text. A value of  P < 0.05 was considered significant.
Study approval. The VAC057 study received ethical approval from the Oxfordshire Research Ethics 
Committee A in the UK (REC reference 14/SC/0120). The study was also reviewed and approved by the 
UK Medicines and Healthcare products Regulatory Agency (MHRA, reference 21584/0331/001-0001). 
Volunteers signed written consent forms, and consent was verified before each vaccination. The trial was 
conducted according to the principles of  the current revision of  the Declaration of  Helsinki 2008 and in full 
conformity with the ICH guidelines for Good Clinical Practice (GCP).
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